Seeking Alpha

HGSI
Human Genome Sciences, Inc.

5/26/2012, 9:10 AM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HGSI Market Currents more »
  • Friday 3:06 PM Human Genome (HGSI +0.6%) should still see a higher bid , says Baird, noting they "remain confident" that a higher bid will emerge despite Glaxo's (GSK +0.3%) indication it will suspend the tender offer while the company's poison pill is in effect. The firm met with management and said their calculations point to a bid closer to $20.
    Comment!
    [Healthcare]
  • Thursday 12:07 PM Human Genome (HGSI -2.4%) slips on a BMO downgrade to Market Perform. THe firm believes the risk of GlaxoSmithKline (GSK) dropping its offer has increased and the likelihood of an significant price increase or a contingent value right for darapladib has been reduced. The firm lowers its price target to $13 from $17.
    Comment!
    [Healthcare, On the Move]
  • Wednesday 8:55 AM GSK (GSK) ammends the conditions of its $2.6B tender offer for Human Genome (HGSI), requiring that the latter redeem or invalidate its poison pill.
    Comment!
    [Healthcare, M&A]
HGSI in Focus more »
HGSI News more »
HGSI Instablog posts more »
  • Top Ten Weekly Movers In April 16-20
    Mon, Apr 23 • James Shaw • Comment!
  • INVESTORS FACE A WEEK OF WHIPSAWS
    Thu, Apr 19 • David Fry • Comment!
  • Human Genome ($HGSI) Announces Rejection Of Unsolicited Offer From Glaxo (GSK) To Acquire HGSI For $13/sh Cash
    Thu, Apr 19 • Michael Sweeney • Comment!
  • Market Forecast + Sector Watch: SPX, Nasdaq, GLD, XME, XLF, BTK, MA, V, GS, JPM, WFC, BAC, REGN, DNDN, MDVN, BIIB, VRTX, HGSI, BTU, CLF, CAT, JOY, WLT
    Mon, Jan 9 • MyHappyTrading • Comment!
  • Biotech Correction Called Back in May & June 2011: Were You Paying Attention?
    Thu, Aug 4, 2011 • Justin M. Hall • Comment!
Write a post on HGSI
HGSI StockTalks
HGSI vs. ETF Alternatives
Company Description

Human Genome Sciences, Inc. (“HGS” or the “Company”) is a commercially focused biopharmaceutical company advancing toward the market with three products in late-stage development: BENLYSTAtm for systemic lupus erythematosus (“SLE”), ZALBINtm for chronic hepatitis C, and raxibacumab for... More

Sector: Healthcare
Industry: Biotechnology
Country: United States